Rallybio Corp

NASDAQ:RLYB   3:59:55 PM EDT
9.78
-0.99 (-9.19%)
Products

Rallybio Announces In-Licensing Of Potential First-In-Class Preclinical Antibody Candidate From Sanofi

Published: 05/10/2022 11:44 GMT
Rallybio Corp (RLYB) - Rallybio Announces In-licensing of Potential First-in-class Preclinical Antibody Candidate From Sanofi.
Rallybio Corp - Under Terms of License Agreement, Co Will Make an Upfront Cash Payment of $3 Million to Sanofi.
Rallybio - Under License Agreement, Co Will Pay Development & Commercial Milestones, & Mid to High Single Digit Royalties on Net Sales to Sanofi.